I
n the heart, increases in contractile load provoked by hypertension or valvular disease promote increases in cardiac mass through the hypertrophy of cardiomyocytes. Injury or death to cardiomyocytes in a portion of the heart places a greater load on cells within uninjured areas and stimulates cellular hypertrophy. Similarly, in familial forms of hypertrophic cardiomyopathy, defects in genes encoding proteins of the sarcomere promote growth in the absence of a stimulus. Hypertrophic hearts are susceptible to abnormalities of cardiac rhythm and have impaired relaxation (diastolic dysfunction), although contractile performance can be preserved. However, when hypertrophic stimuli are unrelieved, the remodeling phenomenon progresses and increasing numbers of cardiomyocytes are replaced with fibrotic scar, which leads to decreased systolic function and circulatory failure.
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Neurotransmitters or hormones that bind to cell surface receptors modulate the rate and force of contraction by regulating the flux of calcium across the cell membrane or released from the sarcoplasmic/endoplasmic reticulum (SR/ ER). In addition, Ca 2ϩ signaling in the cardiomyocyte regulates the long-term remodeling responses of the heart to changing workloads by altering Ca 2ϩ -dependent gene expression and metabolism. 1 In this way, Ca 2ϩ can sense and respond to changes in muscle contraction through a link with hypertrophic gene expression. 2 It is not intuitively obvious, however, how these Ca 2ϩ signals could serve simultaneously as the proximate signal to control cardiac mass, specialized programs of gene expression, and the contractile and metabolic capacities of cardiomyocytes. Ca 2ϩ -dependent signaling events activated by increased contractile load somehow must be insensitive to the large fluctuations in cytosolic calcium that occur as a function of ambient contractile activity. This consideration may explain why although Ca 2ϩ -dependent signal transduction pathways that modulate gene expression have been well defined in other cell types for many years, only recently have similar signaling mechanisms been implicated in excitable cells such as striated muscle.
Hemodynamic stress and neurohormonal stress activate calcium-dependent signaling cascades governed by the serine-threonine phosphatase calcineurin and calmodulin kinase. 3, 4 In this way, Ca 2ϩ -calmodulin-dependent growth pathways in cardiomyocytes interpret changes in Ca 2ϩ transients and activate remodeling events that lead to cardiac hypertrophy and, if left unchecked, eventually heart failure. It is likely then that understanding the molecular mechanism that accounts for the changes in Ca 2ϩ transients to the cardiomyocytes may lead to better therapeutic strategies for cardiac hypertrophy and failure. In fact, research over the last several decades has sought to understand how cardiac stress alters Ca 2ϩ transients in cardiomyocytes. Several groups have asserted that defects in SR calcium uptake (SERCA), abnormalities in excitation-contraction coupling (L-type Ca 2ϩ channel and ryanodine receptor), and reverse-mode sodiumcalcium exchange represent just some of the possible lesions that account for the disturbances in Ca 2ϩ signaling of hypertrophied cardiomyocytes. It is unlikely, however, that a single culprit channel or transporter induces the complex changes that alter [Ca ϩ2 ] i in the stimulated cardiomyocyte. In fact, cross talk among channels, transporters, and pumps integrates calcium cycling in the cardiomyocyte to achieve coordinated excitation-contraction coupling. Thus, it is likely that multiple inputs to the cross talk fail in the myocyte and manifest as SR calcium store depletion, increased arrhythmias, and altered contractility. Moreover, augmented neurohormonal activation of the failing heart may modulate this cross talk and further influence the SR Ca 2ϩ store content. Recently, store-operated calcium entry (SOCE) has emerged as a potential mechanism to alter Ca 2ϩ in the cardiomyocyte. [5] [6] [7] [8] It is likely that Ca 2ϩ entry through storeoperated calcium channels effects changes in gene profiles governed by calcineurin/NFAT (nuclear factor of activated T cell) signaling, as has been shown for lymphocytes and muscle cells. Recently, several groups simultaneously identified stromal interaction molecule 1 (STIM1) and Orai1 channels as the key molecules responsible for SOCE. 9 -11 STIM1 is a single-pass membrane protein found initially as a surface protein in bone marrow stromal cells, where it activated genetic programs required for B-lymphocyte differentiation. 12 Subsequent work has shown that the EF hands of STIM1 bind Ca 2ϩ from the lumen of the ER/SR and thereby sense Ca 2ϩ store content. On depletion of the SR/ER stores and reduced binding of Ca 2ϩ to STIM1, STIM1 migrates underneath the plasma membrane and activates Orai1 channels. 13 STIM1 may also have additional cellular functions, including ER remodeling, which involves a physical interaction with the microtubule protein EB1 and a surface membrane protein. 14 stores for cardiac contraction (Ca 2ϩ -induced Ca 2ϩ release). STIM1 may also inhibit LTCC, as recently indicated by 2 independent groups in smooth muscle and neurons. 16, 17 Here, STIM1 limits the surface expression of the LTCC to promote Ca 2ϩ entry through Orai1 channels. Future studies will have to address whether STIM1 similarly inhibits the cardiac LTCC in cardiomyocytes, because alterations in LTCC are believed to have an important role in the Ca 2ϩ signaling of hypertrophic cardiomyocytes. In the present study, the authors characterize 2 separate STIM1-dependent currents recorded from adult cardiomyocytes isolated from rats subjected to pressure overload. The features of the first current include inward rectification and resemble Orai1-activated currents in pharmacological profile. However, this current is fully active even when Ca 2ϩ stores are replete. This work therefore joins a growing number of studies, including those from my own laboratory, that show the kinetics of I SOCE activation in skeletal and cardiac myocytes are more rapid than that from nonexcitable cells. 18, 19 This more rapid activation and storeindependent current may be explained by the constitutive association of STIM1 and Orai1 at the membrane, as seen in the more immature myotubes. The second STIM1-dependent current is a large, nonselective cation current activated by the depletion of Ca 2ϩ stores with thapsigargin and may represent a series of Ca 2ϩ currents activated by the thapsigargininduced increase in [Ca 2ϩ ] c . In fact, STIM1 is known to activate several transient receptor potential (TRP) channels, many of which have been implicated in cardiac hypertrophy. 20 The difficulty in separating these currents points out that a major obstacle in this field is the lack of adequate pharmacological tools to activate and inhibit SOCE channels. As a result, genetic modification of STIM1 in mice may provide the best way to understand the contributions of STIM1 to cardiac growth and hypertrophy.
The importance of STIM1 in striated muscle is highlighted by my own group's recent description of mice that lack STIM1 (STIM1 Ϫ/Ϫ ), as well as by the discovery of humans who bear mutations in Orai1 21 or STIM1. 22 
STIM1
Ϫ/Ϫ mice manifest a profound reduction in skeletal muscle mass and die of a skeletal myopathy. In fact, we have now validated our findings using an isolated skeletal muscle knockout approach in which the deletion of STIM1 only in skeletal muscle recapitulates the defects in growth and myopathy reported in the STIM1 Ϫ/Ϫ mice (unpublished results). Similarly, patients bearing loss-of-function mutations in the Orai1 and STIM1 genes display a clinical syndrome that includes severe combined immunodeficiency and a skeletal myopathy. In neither the human or murine model of a STIM1-deficient state has a cardiac defect been established, and the cellular hypertrophy required for development appears to be intact in these models. In fact, as reported in the present work by Hulot et al, 15 
Ϫ/Ϫ mice exhibit no differences in cardiac mass or cardiac function from their wild-type counterparts, as determined by echocardiography. However, the present study also examined the effect of STIM1 knockdown by cardiotrophic adeno-associated virus on adult rat hearts subjected to pressure overload. Even with a modest reduction in STIM1 expression, the hearts of short hair pin STIM1 (shSTIM1)-treated rats were protected from the consequences of pressure overload. Here, shSTIM1-treated hearts displayed reduced left ventricular mass and thickness that corresponded to reduced collagen deposition and reduced calcineurin/NFAT signaling. Importantly, the present study demonstrates that reducing STIM1 in the adult heart blunts the hypertrophic response, and this study is the first to suggest a role for STIM1 in the adult heart. Therefore, although STIM1 may not be important for heart development or for developmental hypertrophy, it may have an increased role in pathological hypertrophy.
It is clear from a growing number of studies that defects in Ca 2ϩ signaling underlying cardiac hypertrophy effect not only cardiac contraction but also the signaling events associated with cardiac growth and metabolism. Understanding the molecular components of this second Ca 2ϩ signaling pathway associated with the hypertrophic program will yield new and innovative therapeutic strategies to address this important clinical problem. STIM1-dependent Ca 2ϩ entry has emerged as a potential target, and more research will be required to best understand how STIM1-Ca 2ϩ entry contributes to the cardiac action potential, the modulation of excitationcontraction coupling, and the hypertrophic program.
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